Skip to content

Esperion Therapeutics ESPR Preferred Stock, Shares Issued

Preferred Stock, Shares Issued at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
BridgeBio Pharma logo
BridgeBio PharmaBBIO
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesIssued.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's preferred stock, shares issued.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's preferred stock, shares issued?
Esperion Therapeutics (ESPR) reported preferred stock, shares issued of $0 in Q1 2026.